Published in J Transl Med on May 26, 2011
AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J Invest Dermatol (2012) 1.09
LINE-1 hypomethylation in blood and tissue samples as an epigenetic marker for cancer risk: a systematic review and meta-analysis. PLoS One (2014) 1.04
Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. J Transl Med (2012) 0.99
LINE-1 hypomethylation in gastric cancer, detected by bisulfite pyrosequencing, is associated with poor prognosis. Gastric Cancer (2012) 0.95
The prognostic value of global DNA hypomethylation in cancer: a meta-analysis. PLoS One (2014) 0.91
The Fine LINE: Methylation Drawing the Cancer Landscape. Biomed Res Int (2015) 0.91
Melanoma epigenetics: novel mechanisms, markers, and medicines. Lab Invest (2014) 0.89
Clinical implications of the LINE-1 methylation levels in patients with gastrointestinal cancer. Surg Today (2013) 0.87
Epigenetic biomarkers in skin cancer. Cancer Lett (2012) 0.84
Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications. Br J Cancer (2012) 0.81
Epigenetic cancer prevention mechanisms in skin cancer. AAPS J (2013) 0.79
Prognostic significance of promoter CpG island hypermethylation and repetitive DNA hypomethylation in stage I lung adenocarcinoma. Virchows Arch (2015) 0.78
DNA Methylation Levels of Melanoma Risk Genes Are Associated with Clinical Characteristics of Melanoma Patients. Biomed Res Int (2015) 0.77
Transposable hypomethylation is associated with metastatic capacity of primary melanomas. Int J Clin Exp Pathol (2013) 0.77
LINE-1 methylation level and prognosis in pancreas cancer: pyrosequencing technology and literature review. Surg Today (2017) 0.76
Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. Clin Epigenetics (2017) 0.75
Prognostic significance of LINE-1 hypomethylation in oropharyngeal squamous cell carcinoma. Clin Epigenetics (2017) 0.75
Epigenetics in cancer. N Engl J Med (2008) 17.36
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res (2004) 7.92
Treatment of metastatic melanoma: an overview. Oncology (Williston Park) (2009) 4.58
A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst (2008) 3.54
The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res (1983) 3.51
The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A (1996) 2.63
Epidemiology of invasive cutaneous melanoma. Ann Oncol (2009) 2.21
Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res (2010) 2.01
Retracted Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene (2005) 1.91
CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res (2009) 1.77
L1 mobile element expression causes multiple types of toxicity. Gene (2008) 1.60
LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. Int J Gynecol Cancer (2007) 1.50
Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol (2005) 1.40
CpG island methylation profiling in human melanoma cell lines. Melanoma Res (2009) 1.35
Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. Clin Cancer Res (2008) 1.32
Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol (2007) 1.30
Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res (2007) 1.23
Comparison of CpG island hypermethylation and repetitive DNA hypomethylation in premalignant stages of gastric cancer, stratified for Helicobacter pylori infection. J Pathol (2009) 1.23
Hypomethylation of intragenic LINE-1 represses transcription in cancer cells through AGO2. PLoS One (2011) 1.18
Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res (2006) 1.18
Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med (2010) 1.17
LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics (2009) 1.17
Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res (2008) 1.17
Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma. J Immunother (2002) 1.17
Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res (1993) 1.05
Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status. J Cell Physiol (2008) 0.97
Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm. Virchows Arch (2008) 0.94
Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma. J Cell Physiol (2010) 0.91
Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome. Leukemia (2006) 0.89
Predicting outcome in melanoma: where are we now? Br J Dermatol (2009) 0.87
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol (2013) 6.79
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med (2010) 4.79
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med (2006) 4.47
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol (2008) 3.82
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer (2004) 3.46
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol (2013) 3.28
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One (2009) 3.10
Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol (2006) 3.03
alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res (2004) 3.00
Intraoperative radiotherapy for breast cancer. Lancet Oncol (2004) 2.91
Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem (2004) 2.90
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors. Int J Cancer (2009) 2.78
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol (2002) 2.57
Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol (2009) 2.53
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol (2004) 2.50
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res (2011) 2.26
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol (2002) 2.26
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res (2007) 2.15
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol (2009) 2.12
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun (2010) 2.07
Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol (2005) 2.05
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol (2012) 2.03
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
Chemotherapy for metastatic melanoma: time for a change? Cancer (2007) 1.99
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol (2012) 1.97
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med (2002) 1.95
Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol (2007) 1.95
Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res (2009) 1.90
Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev (2002) 1.84
Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol (2006) 1.83
TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Semin Radiat Oncol (2005) 1.83
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res (2009) 1.78
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
IL-18-induced CD83+CCR7+ NK helper cells. J Exp Med (2005) 1.76
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol (2010) 1.73
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol (2013) 1.67
A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res (2009) 1.64
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med (2014) 1.59
The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol (2011) 1.57
Interferon alfa-2a for melanoma metastases. Lancet (2002) 1.55
Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene (2003) 1.49
Epidemiology of Kaposi's Sarcoma herpesvirus (HHV8) in Västerbotten County, Sweden. J Med Virol (2006) 1.47
Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability. Oncogene (2004) 1.46
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes. Int J Cancer (2012) 1.45
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res (2013) 1.43
Microrna profiling analysis of differences between the melanoma of young adults and older adults. J Transl Med (2010) 1.39
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother (2009) 1.36
Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res (2007) 1.35
New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol (2003) 1.34
Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding. Clin Cancer Res (2008) 1.34
Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother (2008) 1.32
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. Cancer Res (2004) 1.31
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother (2013) 1.30
Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol (2007) 1.30
Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol (2004) 1.30
Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med (2008) 1.28
5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res (2002) 1.27